Search

everythinglearnresearchcommunity

for

Search:↓

Topical treatments can deliver active molecules to skin stem cells, potentially helping treat skin and hair disorders, including skin cancers and hair loss.

FOL-005, a hair growth promoter, acts locally on mouse skin where injected and could be a promising hair loss treatment.

Higher levels of nidogen1 and type IV collagen are found in basal cell carcinoma compared to normal skin.

Damaged hair follicles make mice more prone to skin inflammation and skin cancer after UV exposure.

Targeting ornithine decarboxylase can help prevent skin cancer.

Noggin promotes skin tumors by activating certain cell signaling pathways.

UV exposure reduces Lgr6+ stem cells in mouse skin and they don't significantly contribute to skin cancer development.

B-Raf and C-Raf are essential for maintaining melanocyte stem cells to prevent hair graying.

Serine is vital for hair follicle stem cells to balance hair growth and skin repair.

Activating Notch signaling can kill basal cell carcinoma cells.

New treatments like nanotechnology show promise in improving skin cancer therapy.

Inhibiting ornithine decarboxylase may help prevent certain skin cancers.

Keratin proteins are essential for keeping the cells in the human colon healthy and stable.

PTEN helps control the number and health of skin stem cells by working with the protein BMAL1.

Blocking certain immune signals can reduce skin damage from radiation therapy.

Lower SMAD2/3 activation predicts more severe skin cancer.

Understanding hair growth pathways can lead to better hair loss treatments.

The type of tumor suppressor affects the form of skin cancer from hair follicle stem cells.

Lacking cyclin D3 reduces skin cancer growth without affecting normal skin cell growth.

Polyamines are crucial for skin tumor development, and inhibiting them can prevent tumors.

BSSP may help skin tumors grow and could be a marker or target for skin cancer treatment.

Blocking specific proteins can help remove aging cells and might treat age-related diseases and promote hair growth.

The oncoprotein causes abnormal hair growth without increasing skin cancer risk.

c-Myc activation in mouse skin increases sebaceous gland growth and affects hair follicle development.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Loss of Dnmt3a and Dnmt3b increases aggressive skin tumors by affecting PPAR-γ.

Patients on dabrafenib and trametinib for melanoma often experience skin side effects.